Quantum Biopharma (QNTM) Income towards Parent Company (2019 - 2026)

Quantum Biopharma has reported Income towards Parent Company for 8 years, with the latest figure at -$2.8 million in Q1 2026.

• Quarterly Income towards Parent Company rose 14.23% year-over-year to -$2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.8 million (up 14.23% YoY) and the FY2025 annual result came in at -$27.0 million, changed N/A from the prior year.
• Income towards Parent Company declined to -$2.8 million in Q1 2026 per QNTM's latest filing, from -$2.3 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$444506.0 in Q1 2022 and troughed at -$34.8 million in Q4 2023.
• A 5-year average of -$6.0 million and a median of -$3.5 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company plunged 2115.35% in 2023, then soared 84.33% in 2024.
• Over 5 years, Income towards Parent Company stood at -$444506.0 in 2022, then slumped by 7731.08% to -$34.8 million in 2023, then jumped by 84.33% to -$5.5 million in 2024, then surged by 57.83% to -$2.3 million in 2025, then dropped by 21.52% to -$2.8 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$2.8 million, -$2.3 million, and -$5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.